Phase 1 Trial of the LSD1 inhibitor sp-2577 in patients with relapsed or refractory Ewing sarcoma
Principal Investigator: Damon Reed, MD, Moffitt Cancer Center
Study Synopsis:
This trial is a targeted treatment for individuals diagnosed with refractory or recurrent Ewing sarcoma. Ewing sarcoma is an aggressive, small round blue cell tumor typically presenting as a primary bone tumor in children and young adults.
This trial will be testing SP-2577, a reversible inhibitor of LSD1, an enzyme that targets EWS/FLI1 activity; the critical pathophysiologic mechanism of Ewing sarcoma, through disruption of the function of associated proteins represents an intriguing strategy for clinical intervention. This concept has been featured in Nature News, an international science publication.
